Form 4 for ARTV Artiva Biotherapeutics, Inc.
Accepted 2025-12-15 00:00:00 ET · period of report 2025-12-15 · accession 0001193125-25-319696 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| T | 2025-12-15 | 2025-12-15 | ARTV | Aslan Fred | Pres, CEO, Dir | S - Sale | $6.00 | -3,187 | 1.21M | -0.3% | -$19.1K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-12-15 | S | D | 3,187 | $6.00 | 1,209,948 | D | — | — | (F1) Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on July 23, 2024. |